United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 47.2% in the 4th quarter, Holdings Channel reports. The firm owned 78,435 shares of the biotechnology company’s stock after selling 70,046 shares during the quarter. Loomis Sayles & Co. L P’s holdings in United Therapeutics were worth $27,675,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the third quarter worth about $33,000. Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $67,000. MassMutual Private Wealth & Trust FSB lifted its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,755 shares of company stock worth $29,792,021 in the last three months. 11.90% of the stock is currently owned by insiders.

United Therapeutics Trading Down 0.9 %

NASDAQ:UTHR opened at $308.02 on Friday. The company has a 50-day moving average of $341.10 and a 200-day moving average of $355.98. The firm has a market cap of $13.83 billion, a price-to-earnings ratio of 13.53, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business posted $4.36 earnings per share. On average, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.